Clinical Trial Update: Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of a norovirus GI.1/GII.4 bivalent VLP vaccine in children has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus

Drugs mentioned

• Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) Vaccine

Snippet

Sponsor: Takeda | Conditions: Norovirus | Phase 2 | Status: COMPLETED | Results posted: 2019-04-01